This site is intended for healthcare professionals

New real-world observational analysis of Uptravi underscores the importance of risk assessment for treating pulmonary arterial hypertension patients.-Johnson & Johnson

Read time: 2 mins
Last updated:10th Apr 2021
Published:11th Apr 2021
Condition: Pulmonary Arterial Hypertension
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest